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ABSTRACT  27 
The airborne route is a potential pathway in the person-to-person transmission of bacterial 28 
strains amongst cystic fibrosis (CF) populations. In this cross-sectional study we investigate 29 
the physical properties and survival of common non-Pseudomonas aeruginosa CF pathogens 30 
generated during coughing. We conclude that Gram-negative bacteria and Staphylococcus 31 
aureus are aerosolised during coughing, can travel up to 4-metres and remain viable within 32 
droplet nuclei for up to 45-minutes. These results suggest airborne person-to-person 33 
transmission is plausible for the CF pathogens we measured.  34 
 35 
INTRODUCTION    36 
Recurrent pulmonary infection characterises cystic fibrosis (CF). Whilst Pseudomonas 37 
aeruginosa is generally the most prevalent respiratory pathogen, Staphylococcus aureus, 38 
Stenotrophomonas maltophilia, Achromobacter and Burkholderia species are common.  39 
Studies have demonstrated genetically indistinguishable strains of P. aeruginosa [1, 2], 40 
Burkholderia cepacia complex species [3] and Mycobacterium abscessus [4] both within and 41 
between CF centre populations. Environmental reservoirs are infrequently identified for these 42 
shared bacterial strains, suggesting possible cross-infection. The airborne route is a possible 43 
mode of person-to-person transmission of P. aeruginosa and M. abscessus, which can be 44 
aerosolised during coughing by people with CF and remain viable within droplet nuclei 45 
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(≤4.7µm in size) for extended durations [4, 5]. The extent of airborne dissemination of other 46 
common CF pathogens is poorly understood.    47 
We studied survival of CF pathogens (other than P. aeruginosa and M. abscessus) in the air 48 
over distance and duration, and compared the results with the survival of P. aeruginosa during 49 
voluntary coughing. It was hypothesised that individuals with CF produce similar levels of 50 
droplet nuclei containing Gram-negative bacteria (GNB) and S. aureus during coughing, which 51 
can travel up to 4-metres (m) and remain viable for up to at 45-minutes (min). 52 
METHODS 53 
Participants ≥14 years, with CF were assigned to either GNB or S. aureus groups based on 54 
positive sputum microbiological results in the prior two years. On the testing day, spirometry 55 
was performed and sputum was collected. 56 
The experimental equipment was comprised of two validated, independent systems to study the 57 
distance travelled and survival duration of bacteria contained in aerosols generated during 58 
coughing [5]. Participants completed five cough experiments; distance studies involved aerosol 59 
sampling at 2 and 4-m, whilst the duration studies involved the aging of cough aerosol samples 60 
for 5, 15 and 45-min prior to extraction [5].  Aerosol sampling was undertaken through an 61 
Andersen Cascade Impactor and cough aerosol cultures were performed. (See online 62 
supplement). 63 
Data were analysed using SPSS version 23 (IBM Corp., N.Y., USA). The experimental unit 64 
was organism. The total colony-forming unit (CFU) counts for sputum and aerosol plates were 65 
compared between GNB and S. aureus after log10 transformation for analysis and back-66 
transformation to the geometric mean for reporting. Where the organism was detected in 67 
sputum samples, a Pearson’s correlation examined correlations between sputum and total 68 
viable aerosol at 2-m for each of the GNB and S. aureus organisms detected. The 2-m distance 69 
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was selected in accordance with current infection control recommendations for separation 70 
between people with CF [6] and correlation data for P. aeruginosa from our recent study was 71 
also reported as a comparison [7].  72 
RESULTS 73 
Population description: Thirty participants (19 males (63.3%)) with mean (SD) age 29.9 (10.4) 74 
years, FEV1 61.9 (25.7) % predicted and BMI 23.6 (4.5) kg/m2 were studied. Twelve participants 75 
had a history of GNB infection, twelve participants had pre-existing S. aureus infection, and 6 76 
participants harboured both a GNB and S. aureus; thereby 18 participants were assigned to each 77 
organism group (Figure 1). One participant (GNB) could not tolerate or complete the 15 and 45-78 
min duration experiments.  79 
Sputum bacteriology: Expectorated sputum samples were provided by 29/30 participants. 80 
Participants with negative or missing sputum cultures were excluded from the analysis.  Of the 18 81 
participants with previous GNB infection, 18 GNB organisms were identified in sputum from 15 82 
participants (three participants harboured two different GNB species): S. maltophilia, n=7; 83 
Achromobacter spp., n=5; Burkholderia spp., n=6; Figure 1. S. aureus was recovered from 84 
16/18 participants with history of infection (Figure 1). The mean (95% CI) sputum bacterial 85 
concentration (CFU/mL x 106) for the GNB group was 7.0 (1.6 – 31) and for the S. aureus 86 
group, 1.3 (0.2 – 7.5) (p=0.13; Table 1). 87 
Aerosol sampling: During the cough experiments, at least one positive aerosol was detected for 88 
15/18 (83%) organisms in the GNB group and 10/16 (63%) in the S. aureus group (p=0.25). 11/18 89 
(61%) GNB organisms were cultured at 4-m, and 9/17 (53%) at 45-min; whereas for the S. aureus 90 
group, 8/16 (50.0%) had viable aerosol at 4-m and 4/16 (25%) at 45-min, with no significant 91 
difference in the number of bacterial CFUs between the groups at any distance or duration (Table 92 
1).  The mean percentage of viable particles cultured in the droplet nuclei size range (≤4.7µm) 93 
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was 66.5 (SD 26.1) for the GNB organism group and 58.2 (SD 26.0) for the S. aureus group 94 
(p=0.46). 95 
Sputum and aerosol bacterial typing: Fourteen viable GNB cultures were detected in cough 96 
aerosols from 13 participants (Figure 1) and each organism had an identical genotype identified 97 
in paired sputum (confirmed by MLST-derived from whole genome sequences) including: S. 98 
maltophilia (n=6); Achromobacter spp. (n=4); and Burkholderia spp. (n=4). Aerosolised 99 
bacteria were not detected for five participants in the GNB group, including the participant who 100 
did not provide a sputum sample. Each participant had distinct strains of GNB species. Ten of 101 
16 participants had S. aureus cultured from their paired sputum and aerosol samples (Figure 1) 102 
and 8/10 had concordant genotypes. Isogenic strains were identified in the aerosol and sputum 103 
samples of the remaining two participants (as determined by single nucleotide polymorphism-104 
based genotyping).  105 
CFU correlations at 2-m: Bacterial sputum and aerosol concentrations were correlated for 106 
GNB species (r=0.50, p=0.035) and S. aureus (r=0.66, p=0.005) compared to r=0.55 (p=0.005) 107 
for P. aeruginosa. 108 
DISCUSSION 109 
Cross-infection of CF pathogens remains a concern, with the airborne route considered a 110 
potential transmission pathway [4, 8]. This study demonstrates that GNB species and S. aureus 111 
commonly recovered from people with CF can be aerosolised during coughing, travel up to 4-112 
m from source and survive within droplet nuclei for up to 45-min, which is similar to airborne 113 
characteristics of P. aeruginosa and M. abscessus [4, 5]. The majority of viable particles were 114 
within the size range potentially capable of airborne dispersal and inhaled airway deposition. 115 
Evidence demonstrating cross-infection of Burkholderia cepacia complex species and 116 
Methicillin-resistant S. aureus is clearly established and possible for some Achromobacter spp. 117 
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strains [3, 6, 9]. With each of the organisms of interest investigated in the current study, routes 118 
of acquisition could also be related to healthcare contact [6, 10]. This study highlights the 119 
potential for person-to-person transmission of common CF bacterial pathogens via the airborne 120 
route. As found in our earlier cough aerosol studies with P. aeruginosa  [5, 7] an association 121 
between aerosol CFUs and sputum CFU concentrations for GNB and S. aureus has been 122 
demonstrated, suggesting those with a higher burden of microbial load in the sputum may pose 123 
a greater risk of airborne transmission. Taken together, these data provide further support for 124 
surgical mask wear to minimise potential cross-infection within CF healthcare facilities [7]. 125 
Study limitations include that the infectious dose to cause bacterial infection in CF is unknown 126 
and it is not possible to quantify individual risk of transmission via the airborne route. 127 
Similarly, the implications for younger children remains undetermined and our findings may 128 
not be representative for all people with CF.   129 
This study has demonstrated that common CF pathogens can be aerosolised during coughing 130 
and survive within droplet nuclei for extended durations, highlighting the importance of 131 
universal infection control practices for all people with CF.  132 
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Table 1: Comparison of the sputum and aerosol concentrations between the GNB and S. aureus groups. 168 
 169 
Sputum parameter; mean* (95% CI) Stratified by organism/s identified in sputum p-value GNB, n=18† S. aureus, n=16 
Sputum bacterial concentration;   
CFU/mL x 106 7.0  (1.6 – 31) 1.3 (0.2  – 7.5) 0.13 
Aerosol parameter; mean* (95% CI) n# GNB aerosol  CFU  n# 
S. aureus aerosol 
CFU p-value  
Distance     
2-metres 14 11 (4 – 28)  9 5 (2 – 10)     0.22 
4-metres 11 20 (7 – 50)  8 7 (2 – 23)  0.14 
Duration      
5-minutes 10 13 (4 – 38)  8 3 (1 – 8)  0.062 
15-minutes ‡ 9 10 (3 – 32)  6 4 (2 – 7)  0.12 
45-minutes ‡ 9 12 (3 – 40)  4 4 (1 – 12)  0.10 
* Geometric mean  170 
† 18 GNB organisms identified from the sputum of 15 participants (three participants had two GNB species detected) 171 
‡ One GNB group participant did not complete the 15 and 45-min duration experiments 172 
# Target organisms identified in sputum that had a positive aerosol detected 173 
Definitions: CFU, colony forming unit; CFU/mL, CFU per millilitre of sputum; CI, confidence interval; GNB, Gram-negative bacteria174 
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